Caraway Therapeutics Inc. patents describe new mucolipin (MCOLN; TRPML) activators reported to be useful for the treatment of aging, cancer, ciliopathies, glycogen and lysosomal storage diseases, macular degeneration, neurodegeneration and autosomal dominant polycystic kidney.